Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > $84B global NASH market by 2029

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on Sep 18, 2021 1:37pm

122 Views

Post# 33883338

RE:RE:RE:$84B global NASH market by 2029

Global diabetes is around $60bil and N.Am is something like $25bil. Total Hepatitis market is around $20bil I think. So maybe it's something between those two globally. No one really knows pricing yet or what insurers will push toward. Given the fuzziness around clear testing, insureres will tamper down pricing expectations.

SPCEO1 wrote: It means annual sales in 2029 will be $84 billion. But that is just hype. The chances of t hat being an accurate statement are very, very low.

longterm56 wrote: Does the statement "The global market for drugs to treat NASH is expected to reach $84 billion by 2029" mean ...

a) in 2029 the annual sales will be $84B?
b) between now and 2029 the cumulative sales will total $84B?

Thanks -

-LT

quote=scarlet1967]
Oramed's Phase 2 Oral Insulin NASH Trial Reaches Over 50% Enrollment - Oramed Pharmaceuticals

Oramed's Phase 2 Oral Insulin NASH Trial Reaches Over 50% Enrollment - Oramed Pharmaceuticals

Oramed Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin Trials - Oramed Pharmaceuticals

“The global market for drugs to treat NASH is expected to reach $84 billion by 2029.”

This is one way to spread the news.

This company seems to be developing mostly oral drugs for diabetes type 1/2 and patients suffering from both diabetes and NASH. Looking through their PRs there were some mentioning of Covid Vaccin. The company and Premas Biotech created a new company Oravax (preclinical covid so far). In the past 12 months their valuation has appreciated by 670%.

Over 4000 followers on Stocktwits, valuation over $660M, over 800k daily volume.

Point is there are no norms re how to spread the news. THTX has an open label cancer trial yet they don’t know anything about it’s progress as per the chat with Ed Nash?Their progresses with regulators for NASH seems to be handled by the secret service until now they are trying to bring it back to spot lights! Shares are currently“ridiculously cheap” for a good reason and the reason is…